Quality & complianceOfficial

Denmark flags supply problems with Nordic Prime's clozapine product Prizapin 100 mg tablets

🇩🇰 DKMA · Mon 26 Oct 2026

DKMA says delivery difficulties are affecting Prizapin 100 mg tablets from Nordic Prime ApS, with the expected end of the disruption listed as unknown.

The Danish Medicines Agency (DKMA, Lægemiddelstyrelsen) has published a supply notice on Prizapin 100 mg tablets, marketed in Denmark by Nordic Prime ApS. The notice is dated 26 October 2026 and reports current problems with supply of the product.

Prizapin contains the active substance clozapine (ATC code N05AH02). DKMA gives the cause as delivery difficulties and does not elaborate on their nature.

The agency lists the expected period of disruption as running from the end of August 2026 to an unknown end date. That suggests the problem began before the notice was published, although the notice does not say whether supply has been fully or only partly interrupted.

The notice does not name alternative products or suggest any mitigation measures. DKMA directs questions about the current status to the company. The notice appears in the agency's section on supply notices for medicines.

What it means for your team

  • Supply-chain and QA teams with Danish exposure should check stock and distribution data for Prizapin 100 mg tablets and contact Nordic Prime ApS for the current status, as DKMA directs.
  • The open-ended duration means continuity planning should not assume a near-term return to normal supply.
  • DKMA's notice gives no cause beyond delivery difficulties and names no alternatives, so any contingency steps will need to come from other sources.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →